A

Aurisco Pharmaceutical Co Ltd
SSE:605116

Watchlist Manager
Aurisco Pharmaceutical Co Ltd
SSE:605116
Watchlist
Price: 21.12 CNY -4.91% Market Closed
Market Cap: 8.5B CNY
Have any thoughts about
Aurisco Pharmaceutical Co Ltd?
Write Note

Aurisco Pharmaceutical Co Ltd
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Aurisco Pharmaceutical Co Ltd
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
A
Aurisco Pharmaceutical Co Ltd
SSE:605116
Cash Equivalents
ÂĄ992.9k
CAGR 3-Years
-88%
CAGR 5-Years
-64%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Aurisco Pharmaceutical Co Ltd
Glance View

Market Cap
8.6B CNY
Industry
Pharmaceuticals

Aurisco Pharmaceutical Co., Ltd. engages in the development and production of pharmaceutical chemicals. The company is headquartered in Taizhou, Zhejiang and currently employs 1,207 full-time employees. The company went IPO on 2020-09-21. The firm's main products are respiratory, cardiovascular, anti-infective and nervous system drugs, including flumethasone, fluticasone propionate, eplerenone, tenofovir, pregabalin and other APIs and intermediates. The firm distributes its products in domestic market and to overseas markets.

Intrinsic Value
34.48 CNY
Undervaluation 39%
Intrinsic Value
Price
A

See Also

What is Aurisco Pharmaceutical Co Ltd's Cash Equivalents?
Cash Equivalents
992.9k CNY

Based on the financial report for Dec 31, 2023, Aurisco Pharmaceutical Co Ltd's Cash Equivalents amounts to 992.9k CNY.

What is Aurisco Pharmaceutical Co Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-64%

Over the last year, the Cash Equivalents growth was -98%. The average annual Cash Equivalents growth rates for Aurisco Pharmaceutical Co Ltd have been -88% over the past three years , -64% over the past five years .

Back to Top